A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis

NCT03029455 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

163

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: VX-659
DRUG: Tezacaftor
DRUG: Ivacaftor
DRUG: VX-659 Matching Placebo
DRUG: Triple Combination (TC) Matching Placebos

Sponsor

Vertex Pharmaceuticals Incorporated